Mwandishi:
ULY CLINIC
Mhariri:
ULY CLINIC
Imeboreshwa:
15 Januari 2026, 23:24:55

Majina ya Dawa za PEP: Kinga ya maambukizi ya Virusi vya UKIMWI Baada ya hatari
Watu wengi wanaotumia PEP (Post-Exposure Prophylaxis) hupata mkanganyiko kuhusu majina ya dawa wanazopewa.Mtu anaweza kuambiwa “umepewa N33”, mwingine “umepewa D17”, huku kwenye kopo au karatasi ya hospitali kukiwa na majina kama Tenofovir, Lamivudine, Dolutegravir.
Makala hii inalenga kueleza kwa uwazi:
Majina ya PEP yanavyotumika
Tofauti kati ya jina la kienyeji, la kisayansi na la kibiashara
Jina lipi ni muhimu zaidi kiafya
PEP ni nini kwa ufupi?
PEP ni mchanganyiko wa dawa za VVU (ARVs) unaotumika baada ya tukio hatarishi, ili kuzuia virusi vya VVU kujiimarisha mwilini.Hutumiwa:
Ndani ya saa 72
Kwa siku 28 mfululizo
Aina za majina ya dawa za PEP
Dawa za PEP zinaweza kuitwa kwa njia tatu tofauti, kulingana na muktadha:
Jina la kienyeji / la kituoni (mf. N33, D17)
Jina la kisayansi (generic name)
Jina la kibiashara (brand name)
Kila moja lina matumizi yake, lakini halibadilishi dawa yenyewe.
1. Majina ya kienyeji au ya kituoni (mf. N33, D17)
Majina haya yanamaanisha nini?
Majina kama N33 au D17:
Si majina halisi ya dawa
Ni misimbo ya ndani inayotumika kwenye vituo vya afya au jamii
Huwakilisha kifurushi cha PEP chenye dawa kamili
Kwa nini hutumika?
Kupunguza unyanyapaa
Kurahisisha mawasiliano
Kulinda usiri wa mgonjwa
📌 N33 ≈ D17 ≈ PEP (ikiwa dawa zake ni sawa)
2. Majina ya kisayansi (Generic names)
Haya ndiyo majina halisi ya dawa, yanayotumiwa na WHO, CDC na wataalamu wa afya duniani kote.
Jedwali: Majina ya Kisayansi ya Dawa za PEP
Jina la Kisayansi | Kundi la Dawa | Kazi yake |
Tenofovir (TDF) | NRTI | Huzuia VVU kujizalisha |
Lamivudine (3TC) | NRTI | Huzuia urudufishaji wa virusi |
Emtricitabine (FTC) | NRTI | Mbadala wa 3TC |
Dolutegravir (DTG) | Integrase inhibitor | Huzuia VVU kujipachika kwenye seli |
Raltegravir (RAL) | Integrase inhibitor | Mbadala wa DTG |
📌 Mchanganyiko wa kawaida wa PEP:TDF + 3TC (au FTC) + DTG
3. Majina ya kibiashara (Brand names)
Haya ni majina yanayotolewa na kampuni zinazotengeneza dawa.Dawa ileile ya kisayansi inaweza kuwa na majina mengi ya kibiashara.
Jedwali: Jina la Kisayansi ↔ Jina la Kibiashara
Jina la Kisayansi | Jina la Kibiashara | Maelezo |
TDF + 3TC + DTG | TLD | Mchanganyiko maarufu Afrika |
Tenofovir + Emtricitabine | Truvada | Hutumika PEP/PrEP |
Dolutegravir | Tivicay | Mara nyingi huongezwa kwenye PEP |
Raltegravir | Isentress | Mbadala wa DTG |
TDF + 3TC | TLE / TDF-3TC | Sehemu ya PEP |
📌 Jina la kibiashara linaweza kubadilika, lakini dawa ndani hubaki ileile.
Jedwali Muhtasari: Majina Yote kwa Pamoja
Aina ya Jina | Mfano | Maana yake |
Jina la kituoni | N33 / D17 | Kifurushi cha PEP |
Jina la kisayansi | TDF + 3TC + DTG | Dawa halisi |
Jina la kibiashara | TLD | Jina la kampuni |
Ni jina lipi ni muhimu zaidi kwa afya yako?
Kwa mgonjwa:
Muhimu zaidi ni kujua unatumia PEP
Kufahamu muda (siku 28)
Kutokukosa dozi
Kwa mtaalamu wa afya:
Jina la kisayansi ndilo muhimu zaidi
Hivyo usipate hofu ukisikia jina tofauti, mradi mchanganyiko wa dawa ni sahihi.
Makosa ya kawaida kuhusu majina ya PEP
❌ “N33 ni dawa tofauti na D17”
✔️ Hapana, mara nyingi ni PEP ileile
❌ “Nikipewa jina tofauti, dawa ni dhaifu”
✔️ Hapana, nguvu ya dawa haitegemei jina
❌ “Majina ya namba ni ya WHO”
✔️ Hapana, ni ya vituo au jamii
Ushauri muhimu kwa wagonjwa
Uliza ni PEP ya siku ngapi
Uliza ni dawa zipi zimo ndani
Fuata maelekezo hata kama jina linaonekana geni
Usishiriki dawa na mtu mwingine
Hitimisho
Majina kama N33 au D17 ni njia rahisi za kurejelea PEP, lakini hayabadilishi dawa yenyewe.Kinacholinda afya yako ni mchanganyiko sahihi wa dawa, kuanza mapema, na kutumia kwa siku 28 bila kukosa dozi.
ULY CLINIC inakushauri uwasiliane na daktari wako kwa ushauri na tiba kabla ya kuchukua hatua yoyote ile baada ya kusoma majibu haya.
Kupata ushauri zaidi au tiba kutoka kwa daktari wa ULY CLINIC bofya hapa au tumia linki ya Pata tiba
Imeandikwa,
15 Januari 2026, 23:24:55
Rejea za mada hii
World Health Organization. Guidelines for HIV post-exposure prophylaxis. Geneva: WHO; 2024.
World Health Organization. Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care. Geneva: WHO; 2023.
World Health Organization. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis. Geneva: WHO; 2019.
Centers for Disease Control and Prevention. Clinical guidance for HIV post-exposure prophylaxis (PEP). Atlanta: CDC; 2025.
Centers for Disease Control and Prevention. Antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV. MMWR Recomm Rep. 2025;74(RR-1):1–45.
U.S. Department of Health and Human Services. Post-Exposure Prophylaxis (PEP) fact sheet. Bethesda (MD): NIH HIVinfo; 2025.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Bethesda (MD): Department of Health and Human Services; 2024.
Horak R, Carmona S, Meintjes G, et al. Southern African HIV Clinicians Society guideline for post-exposure prophylaxis: Updated recommendations. S Afr J HIV Med. 2023;24(1):1522.
Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM). Australian national guidelines for post-exposure prophylaxis after HIV exposure. 4th ed. Sydney: ASHM; 2025.
Günthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2024 recommendations. JAMA. 2024;331(5):403–25.
Flexner C. Antiretroviral agents and treatment of HIV infection. In: Brunton LL, Hilal-Dandan R, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill; 2023. p. 1623–55.
HIV Drug Interactions. Dolutegravir, tenofovir and lamivudine drug profiles. University of Liverpool; 2024.
